Share price · ALT
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when ALT's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 18 Nov 2026-9.2%
Nothing announced by ALT that day or the session before.
- 12 Nov 2026-16.6%
- 10 Nov 2026-8.5%
- 14 Oct 2026-4.9%
Nothing announced by ALT that day or the session before.
- 24 Sep 2026-4.7%
- 4 Sep 2026+5.9%
- 2 Sep 2026+6.1%
Nothing announced by ALT that day or the session before.
- 3 Aug 2026+5.6%
- 27 Jul 2026+6.9%
Nothing announced by ALT that day or the session before.
- 1 May 2026+8.5%
Nothing announced by ALT that day or the session before.
Share of unusual movement by asset
For each asset, the share of ALT's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | GLP-1/glucagon receptor (dual)Peptide | MASH / NASH |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $27M | $29M+ $236M short-term inv. | $32M-$38M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $19M | $63M+ $263M short-term inv. | $23M-$24M operating cash flow | report ↗ |
| 2026-Q1 | — | $16M | $98M+ $234M short-term inv. | $23M-$21M operating cash flow | report ↗ |
| 2025-Q3 | <$0.1M | $15M | $61M+ $150M short-term inv. | $19M-$12M operating cash flow | report ↗ |
| 2025-Q2 | <$0.1M | $17M | $183M | $22M-$19M operating cash flow | report ↗ |
| 2025-Q1 | <$0.1M | $16M | $49M+ $101M short-term inv. | $20M-$17M operating cash flow | report ↗ |
| 2024-Q3 | <$0.1M | $20M | $32M+ $108M short-term inv. | $23M-$27M operating cash flow | report ↗ |
| 2024-Q2 | <$0.1M | $21M | $57M+ $108M short-term inv. | $25M-$18M operating cash flow | report ↗ |
| 2024-Q1 | <$0.1M | $21M | $79M+ $103M short-term inv. | $24M-$16M operating cash flow | report ↗ |
| 2023-Q3 | $0.4M | $18M | $87M+ $54M short-term inv. | $21M-$20M operating cash flow | report ↗ |
| 2023-Q2 | <$0.1M | $13M | $102M+ $58M short-term inv. | $16M-$19M operating cash flow | report ↗ |
| 2023-Q1 | <$0.1M | $17M | $105M+ $61M short-term inv. | $20M-$19M operating cash flow | report ↗ |
| 2022-Q3 | $0 | $20M | $128M+ $74M short-term inv. | $24M-$15M operating cash flow | report ↗ |
| 2022-Q2 | <$0.1M | $16M | $136M+ $49M short-term inv. | $20M-$17M operating cash flow | report ↗ |
| 2022-Q1 | <$0.1M | $15M | $180M | $19M-$14M operating cash flow | report ↗ |
| 2021-Q3 | — | $29M | $175M+ $25M short-term inv. | $34M-$18M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | <$0.1M | $66M | $44M+ $230M short-term inv. | $22M-$68M operating cash flow | report ↗ |
For the full year 2025, Altimmune reported revenue of $0.04M, up 100.0% YoY, with R&D spend of $66.43M, down 19.2% YoY. Cash and equivalents were $43.8M, and the company reported a net loss of $88.09M.
The company plans to initiate a Phase 3 MASH trial in 2026 and received FDA Breakthrough Therapy Designation for pemvidutide in MASH, with topline data from the Phase 2 RECLAIM trial in alcohol use disorder expected in Q3 2026. The Phase 2 RESTORE trial in alcohol-associated liver disease is enrolling, Jerry Durso was appointed CEO, and the balance sheet was strengthened through a $75M registered direct offering in January 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | <$0.1M | $82M | $37M+ $95M short-term inv. | $24M-$80M operating cash flow | report ↗ |
| 2023-FY | $0.4M | $66M | $135M+ $63M short-term inv. | $22M-$76M operating cash flow | report ↗ |
| 2022-FY | -$0.1M | $71M | $111M+ $74M short-term inv. | $21M-$63M operating cash flow | report ↗ |
| 2021-FY | $4.4M | $75M | $190M | $24M-$78M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 15 purchases ($466K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-18 | MENZIUSO RICHARD THOMAS · Principal Accounting Officer | Open-market purchase | 10,000 | $1.42 | $14K | Form 4 |
| 2026-11-13 | Durso Jerome Benedict · director, President and CEO | Open-market purchase | 30,700 | $1.62 | $50K | Form 4 |
| 2026-11-13 | Pisano Wayne · director | Open-market purchase | 10,000 | $1.64 | $16K | Form 4 |
| 2026-11-13 | WEAVER GREGORY L · Chief Financial Officer | Open-market purchase | 10,000 | $1.62 | $16K | Form 4 |
| 2026-11-11 | WEAVER GREGORY L · Chief Financial Officer | Option exercise | 18,750 | — | — | Form 4 |
| 2026-11-11 | WEAVER GREGORY L · Chief Financial Officer | Tax withholding | 5,672 | $1.93 | $11K | Form 4 |
| 2026-11-11 | WEAVER GREGORY L · Chief Financial Officer | Option exercise (derivative) | 18,750 | — | — | Form 4 |
| 2026-11-02 | Howarth Alex G. · director | Award / grant (derivative) | 160,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 171 reporting institutions held 69.3M shares ($212.1M, 35.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 12,795,277 | $39.4M |
| 2 | STATE STREET CORP | 7,145,550 | $22.0M |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 5,658,049 | $17.4M |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 5,382,002 | $16.6M |
| 5 | MARSHALL WACE, LLP | 4,017,901 | $12.4M |
| 6 | MILLENNIUM MANAGEMENT LLC | 3,258,191 | $10.0M |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 3,107,096 | $9.6M |
| 8 | Alyeska Investment Group, L.P. | 2,644,600 | $8.1M |
| 9 | TWO SIGMA INVESTMENTS, LP | 2,478,900 | $7.6M |
| 10 | Nuveen, LLC | 2,334,601 | $7.2M |
| 11 | GOLDMAN SACHS GROUP INC | 1,350,649 | $4.2M |
| 12 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,325,956 | $4.1M |
| 13 | DIMENSIONAL FUND ADVISORS LP | 1,045,926 | $3.2M |
| 14 | NORTHERN TRUST CORP | 996,721 | $3.1M |
| 15 | UBS Group AG | 904,768 | $2.8M |